Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Схожие документы

• Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
  по: Burkhard Tümmler, и др.
  Опубликовано: (2023-03-01)
• Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
  по: Seth A. Reasoner, и др.
  Опубликовано: (2024-02-01)
• Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis
  по: Carina M. E. Hansen, и др.
  Опубликовано: (2026-03-01)
• Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programmeResearch in context
  по: Pierre-Régis Burgel, и др.
  Опубликовано: (2025-10-01)
• One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes
  по: Alice Castaldo, и др.
  Опубликовано: (2024-01-01)